‘Chinese coronavirus vaccine efficacy is 91.25%, likely to increase’

‘Chinese coronavirus vaccine efficacy is 91.25%, likely to increase’

Brazil so far has no agreements to import vaccine made by American companies Pfizer or Moderna, which have been approved by US and other nations.

A COVID-19 vaccine developed by China's Sinovac Biotech is 91.25% effective, according to interim data from a late-stage trial in Turkey, a potentially much better result than reported from a separate trial of the vaccine in Brazil.

Sinovac developed CoronaVac in early 2020 and then carried out a series of clinical trials.

'With regard to the Scientific Committee's information on potential side effects of the vaccine, only 2.5 percent of the volunteers experienced mild headaches and mild fatigue.

The researchers, part of the government's science council, said no major symptoms were detected during CoronaVac's trials in Turkey, apart from one person who became allergic.

Explaining the reasons why Turkey prefers an inactivated vaccine platform when choosing a vaccine against COVID-19, Koca said that developing a vaccine on this platform is the most proven method for Turkey.

The phase-3 studies of Chinese vaccine producer Sinovac's inactive virus vaccine CoronaVac were launched in Turkey on September 14.

Turkey prefers Sinovoc's vaccine because it's an inactive vaccine, the minister emphasized.

Pakistan's de facto health minister Dr Faisal Sultan said earlier this month that they were negotiating with China and Russian Federation, among others, to procure coronavirus vaccines.

Turkey "will be able to vaccinate 1.5 million or even 2 million people per day", he said, adding that the "first stage" of vaccinations will cover 9 million people. Both countries are running phase 3 trials and have yet to approve the vaccine, whose trial data is expected within days.

The company then moved on to Phase 3 trials in Brazil, Indonesia and Turkey, countries with high COVID-19 rates.

Related Articles